Shattuck Labs, Inc. · NASDAQ:STTK

Shattuck Labs — European Crohn's and Colitis Organization 2025

9 slides from Shattuck Labs's conference presentation, Feb 20, 2025

  1. Slide 1: Preclinical Development of SL-325, a High Affinity DR3 Blocking Antibody

    Preclinical Development of SL-325, a High Affinity DR3 Blocking Antibody, for Durable Blockade of the TL1A/DR3 Axis in Inflammatory Bowel Disease European Crohn's and Colitis Organization – 2025 Dr. Taylor H. Schreiber, MD/PhD Nasdaq: STTK February 20, 2025 1

  2. Slide 2: Forward-Looking Statements

    Forward-Looking Statements This presentation contains “forward-looking statements” within the meaning of the federal securities laws, which statements are subject to substantial risks and uncertainties and are based on our estimates and assumptions. All statements, other than statements of historica

  3. Slide 3: SL-325 Is a High-Affinity DR3-Specific Blocking Antibody

    SL-325 Is a High-Affinity DR3-Specific Blocking Antibody Crohn’s Disease is TL1A is less abundant than DR3 in characterized by actively inflamed areas Tissue Lymphoid Cells discontinuous and Resident APCs In Blood and Tissue migratory inflammation 8.4% TL1A 17.4% DR3 Expression Expression TL1A DR3 S

  4. Slide 4: SL-325 NHP Study Design and Safety Overview

    SL-325 NHP Study Design and Safety Overview Compound Dose Level Treatment Period Recovery Period 1 mg/kg (3 Male, 3 Female) 10 mg/kg (3 Male, 3 Female) 100 mg/kg SL-325 (5 Male, 5 Female) Day 1 15 29 4 weeks ➔ IND-enabling GLP toxicology study in cynomolgus macaques ➔ No-observed-adverse effect leve

  5. Slide 5: Achieved Full and Durable Receptor Occupancy (RO)

    SL-325 Achieved Full and Durable Receptor Occupancy (RO) Copy of Drug Conc. vs ADA_Day 29 Day 29 on study Receptor Occupancy (%) 125 Full RO 100 1 mg/kg 106 1 mg/kg SL-325 Conc. (ng/mL) 10 mg/kg 105 75 10 mg/kg 100 mg/kg 50 104 100 mg/kg 1mg/ml 25 103 102 0 101 <50% RO se y 1 y 7 15 22 43 57 100 o d

  6. Slide 6: Showed No Signs of DR3 Agonism

    SL-325 Showed No Signs of DR3 Agonism %Tregs (CD4+ T Cells) %Ki67+ (CD4+ T Cells) 8 10 Vehicle CD25+FoxP3+ (%) Vehicle 1 mg/kg8 1 mg 6 Ki67+ (%) 10 mg/kg 10 mg 4 6 100 mg/kg 100 mg/kg 4 2 2 0 0 se 1 7 15 22 se 1 7 15 22 ay ay ay ay do do ay ay ay ay D D D D e- e- D D D D Pr Pr ➔ DR3 activation cause

  7. Slide 7: Projected Dose and Schedule in Human Subjects

    Projected Dose and Schedule in Human Subjects SL-325 Concentration (mcg/mL) Q2W Induction → Q4W Maintenance Q2W Induction → Q8W Maintenance Time (weeks) Time (weeks) ➔ 3 - 6 mg/kg dosing at Q2W induction and Q4-8W maintenance expected to provide Ctrough concentration > 1 µg/mL to achieve full RO in

  8. Slide 8: SL-325 Expected to Enter Clinical Development in 2025 as a First-In-Class DR3 Blocking Antibody

    SL-325 Expected to Enter Clinical Development in 2025 as a First-In- Class DR3 Blocking Antibody Favorable Safety Full RO and Lack of Differentiation from Profile DR3 Agonism TL1A Blocking mAbs ✓ NOAEL is the top dose of 100 ✓ Full RO starting at 1 mg/kg, ✓ Immune complex formation and mg/kg durable

  9. Slide 9: Thank You

    Thank You Investor Relations InvestorRelations@ShattuckLabs.com 9

Shattuck Labs — European Crohn's and Colitis Organization 2025 on 6ix